[Federal Register Volume 62, Number 130 (Tuesday, July 8, 1997)]
[Notices]
[Page 36558]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-17679]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 97M-0274]


Perclose, Inc.; Premarket Approval of Prostar 
Percutaneous Vascular Surgical (PVS) System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its 
approval of the application by Perclose, Inc., Menlo Park, CA, for 
premarket approval, under the Federal Food, Drug, and Cosmetic Act (the 
act), of Prostar Percutaneous Vascular Surgical (PVS) System. 
FDA's Center for Devices and Radiological Health (CDRH) notified the 
applicant, by letter of April 30, 1997, of the approval of the 
application.

DATES: Petitions for administrative review by August 7, 1997.

ADDRESSES: Written requests for copies of the summary of safety and 
effectiveness data and petitions for administrative review to the 
Dockets Management Branch (HFA-305), Food and Drug Administration, 
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Christopher M. Sloan, Center for 
Devices and Radiological Health (HFZ-450), Food and Drug 
Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-
8243.

SUPPLEMENTARY INFORMATION: On November 26, 1996, Perclose, Inc., Menlo 
Park, CA 94025, submitted to CDRH an application for premarket approval 
of Prostar PVS System. The Prostar PVS System 
consists of the Prostar PVS Device (9 and 11 French sizes) 
and the following accessories: A Prostar Pre-Dilator (9 and 
11 French sizes), a Perclose Knot Pusher, a Prostar 
Transition Guidewire, and a Perclose Arterial Tamper. The 
device is a vascular hemostasis device and is indicated for the 
percutaneous delivery of sutures for closing the common femoral artery 
access site and reducing the time to hemostasis and ambulation (time-
to-standing) of patients who have undergone interventional procedures 
using 8 and 11 French sheaths.
    In accordance with the provisions of section 515(c)(2) of the act 
(21 U.S.C. 360e(c)(2)) as amended by the Safe Medical Devices Act of 
1990, this premarket approval application (PMA) was not referred to the 
Circulatory System Devices Panel of the Medical Devices Advisory 
Committee, an FDA advisory committee, for review and recommendation 
because the information in the PMA substantially duplicates information 
previously reviewed by this panel.
    On April 30, 1997, CDRH approved the application by a letter to the 
applicant from the Director of the Office of Device Evaluation, CDRH.
    A summary of the safety and effectiveness data on which CDRH based 
its approval is on file in the Dockets Management Branch (address 
above) and is available from that office upon written request. Requests 
should be identified with the name of the device and the docket number 
found in brackets in the heading of this document.

Opportunity for Administrative Review

    Section 515(d)(3) of the act authorizes any interested person to 
petition, under section 515(g) of the act, for administrative review of 
CDRH's decision to approve this application. A petitioner may request 
either a formal hearing under 21 CFR part 12 of FDA's administrative 
practices and procedures regulations or a review of the application and 
CDRH's action by an independent advisory committee of experts. A 
petition is to be in the form of a petition for reconsideration under 
21 CFR 10.33(b). A petitioner shall identify the form of review 
requested (hearing or independent advisory committee) and shall submit 
with the petition supporting data and information showing that there is 
a genuine and substantial issue of material fact for resolution through 
administrative review. After reviewing the petition, FDA will decide 
whether to grant or deny the petition and will publish a notice of its 
decision in the Federal Register. If FDA grants the petition, the 
notice will state the issue to be reviewed, the form of the review to 
be used, the persons who may participate in the review, the time and 
place where the review will occur, and other details.
    Petitioners may, at any time on or before August 7, 1997, file with 
the Dockets Management Branch (address above) two copies of each 
petition and supporting data and information, identified with the name 
of the device and the docket number found in brackets in the heading of 
this document. Received petitions may be seen in the office above 
between 9 a.m. and 4 p.m., Monday through Friday.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under 
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) 
and redelegated to the Director, Center for Devices and Radiological 
Health (21 CFR 5.53).

    Dated: June 17, 1997.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and 
Radiological Health.
[FR Doc. 97-17679 Filed 7-7-97; 8:45 am]
BILLING CODE 4160-01-F